MAPT and tauopathy: Tau aggregation, encompassing oligomerisation and fibril formation, is considered a central event in the pathogenesis of AD and other tauopathies, making it a compelling target for drug discovery and development.[8] However, the molecular and cellular factors that initiate tau misfolding and aggregation and drive the spread of tau pathology within the brain remain elusive.